Copeptin in Childhood Epilepsy (EpiCop)

University Hospital Basel logo

University Hospital Basel

Status

Completed

Conditions

Febrile Seizures
Epilepsy
Children

Study type

Observational

Funder types

Other

Identifiers

NCT01884766
EKBB 352/12

Details and patient eligibility

About

In many fields of medicine, except seizure disorders, blood biomarkers have captured an integrated part of diagnostic decision making, including copeptin, the surrogate marker of vasopressin release. There are strong arguments to hypothesize circulating copeptin is elevated in epilepsy, especially in generalized seizures such as fever seizures (FS), and that copeptin is predictive for complexity and relapse at least in FS. Although long-term morbidity and mortality are both low in FS, there is high anxiety among parents because of a lack of criterions to identify children at risk for relapse. Copeptin may fill this gap by adding important diagnostic and prognostic information. Eventually, less children may receive needlessly over years fever drugs or anti-epileptic drugs.

Full description

Background: Copeptin is a surrogate marker of the pituitary-secreted nonapeptide arginine-vasopressin (AVP) and has gradually replaced AVP in several clinical studies largely due to its structural and methodological advantages. Copeptin is a marker of non-specific stress response, and has been suggested to have clinical implications in a variety of cardiovascular and non-cardiovascular conditions. However, up to now there are no data available on copeptin in seizure disorders, neither in adults nor in children. Working hypotheses: Circulating copeptin concentrations are increased after generalized seizures, including FS. Copeptin is predictive for complexity and relapse in FS. Specific aims: to determine copeptin concentrations in children below six years after generalized seizures, either unrelated or related to fever (FS), and in control children below six years without seizures. to compare copeptin concentrations with blood-gas parameters (including hydrogen ion concentration (pH), base deficiency, and carbon dioxide), lactate, sodium, chloride, C reactive protein (CRP), and prolactin.

Enrollment

340 patients

Sex

All

Ages

Under 5 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria epilepsy-cohort:

  • All kind of seizures leading to presentation
  • Age below 6 years

Inclusion Criteria control-cohort:

  • Fever without seizures caused by banal infections
  • Age below 6 years

Exclusion Criteria:

No blood required for medical reasons

Trial design

340 participants in 2 patient groups

Epilepsy
Description:
All kind of epilepsy, including febrile seizures
Control
Description:
children without seizures at presentation in the emergency but fever due to banal infections

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems